In a groundbreaking study, researchers demonstrated that the experimental immunosuppressive drug tegoprubart may allow Type 1 diabetes patients to effectively receive islet cell transplants without needing insulin.
The results show that patients who received islet cell transplants with tegoprubart experienced significant benefits, with two patients completely eliminating their insulin needs and achieving normal A1C levels.
Dr. Piotr Witkowsky emphasized the significance of balancing the immune suppression to prevent rejection of the transplanted material while minimizing adverse effects on the patients.
This study suggests the potential of innovative immunosuppressive therapies for Type 1 diabetes, raising hope for improved outcomes in islet cell transplantation.
Collection
[
|
...
]